论文部分内容阅读
重组人Ⅱ型肿瘤坏死因子受体—抗体融合蛋白作为一种生物制剂及TNF-a拮抗剂已经广泛应用于成人类风湿的临床治疗,取得了很好的疗效,已经证实其能抑制骨破坏,延缓病情进展,减少致残率[1]。本组研究将其应用于幼年特发性关节炎(JIA),评价其与传统的甲氨蝶呤治疗在疗效及不良反应方面的区别。1资料与方法
As a biological agent and TNF-a antagonist, recombinant human Tumor necrosis factor receptor-antibody fusion protein type 2 has been widely used in the clinical treatment of rheumatoid arthritis in adults and has achieved good curative effect. It has been proved that it can inhibit bone destruction, Delay the progression of the disease, reduce the disability rate [1]. This group of studies will be applied to juvenile idiopathic arthritis (JIA), evaluation and traditional methotrexate treatment in the efficacy and adverse reactions differences. 1 data and methods